IDEXX Laboratories, Inc. (LON:0J8P)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 40.31B |
| Revenue (ttm) | 3.10B |
| Net Income (ttm) | 764.34M |
| Shares Out | n/a |
| EPS (ttm) | 9.37 |
| PE Ratio | 52.74 |
| Forward PE | 48.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,338 |
| Average Volume | 339 |
| Open | 675.54 |
| Previous Close | 675.19 |
| Day's Range | 675.54 - 696.92 |
| 52-Week Range | 351.94 - 771.52 |
| Beta | 1.67 |
| RSI | 49.98 |
| Earnings Date | Feb 2, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference... [Read more]
Financial Performance
In 2024, IDEXX Laboratories's revenue was $3.90 billion, an increase of 6.46% compared to the previous year's $3.66 billion. Earnings were $887.87 million, an increase of 5.07%.
Financial numbers in USD Financial StatementsNews
Here's How Much $1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today
IDEXX Laboratories (NASDAQ: IDXX) has outperformed the market over the past 10 years by 11.91% on an annualized basis producing an average annual return of 25.31%. Currently, IDEXX Laboratories has a...
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
Veracyte stands out in a pressured medical instruments industry as genAI adoption and rising sales forecasts fuel investor interest.
$100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today
IDEXX Laboratories (NASDAQ: IDXX) has outperformed the market over the past 20 years by 2.98% on an annualized basis producing an average annual return of 11.79%. Currently, IDEXX Laboratories has a ...
$1000 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today
IDEXX Laboratories (NASDAQ: IDXX) has outperformed the market over the past 20 years by 3.19% on an annualized basis producing an average annual return of 12.05%. Currently, IDEXX Laboratories has a ...
Barclays Initiates Coverage on IDEXX Laboratories (IDXX) with Overweight Rating | IDXX Stock News
Barclays Initiates Coverage on IDEXX Laboratories (IDXX) with Overweight Rating | IDXX Stock News
Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If You Invested $1000 in Idexx Laboratories 10 Years Ago, This Is How Much You'd Have Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now?
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Idexx (IDXX) Upgraded to Buy: Here's What You Should Know
Idexx (IDXX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
P/E Ratio Insights for IDEXX Laboratories
In the current session, the stock is trading at $766.68, after a 1.93% spike. Over the past month, IDEXX Laboratories Inc. (NASDAQ: IDXX) stock increased by 20.86% , and in the past year, by 81.78% ....
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may b...
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 10 Years
IDEXX Laboratories (NASDAQ: IDXX) has outperformed the market over the past 10 years by 14.09% on an annualized basis producing an average annual return of 26.23%. Currently, IDEXX Laboratories has a...
Baron Asset Fund Q3 2025 Performance Review
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT...
Agree To Buy Idexx Laboratories At $600, Earn 5.3% Annualized Using Options
Investors considering a purchase of Idexx Laboratories, Inc. (Symbol: IDXX) shares, but cautious about paying the going market price of $701.05/share, might benefit from considering selling puts among...
IDXX Quantitative Stock Analysis
Below is Validea's guru fundamental report for IDEXX LABORATORIES INC (IDXX). Of the 22 guru strategies we follow, IDXX rates highest using our Multi-Factor Investor model based on the published strat...
IDEXX Laboratories (IDXX) Sees Target Price Raised by Morgan Stanley | IDXX Stock News
IDEXX Laboratories (IDXX) Sees Target Price Raised by Morgan Stanley | IDXX Stock News
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
IDXX: JP Morgan Raises Price Target to $775, Maintains Overweight Rating | IDXX Stock News
IDXX: JP Morgan Raises Price Target to $775, Maintains Overweight Rating | IDXX Stock News
IDEXX Laboratories: A Strong Third Quarter With Good Future Prospects
IDXX: BTIG Raises Price Target to $830, Maintains Buy Rating | IDXX Stock News
IDXX: BTIG Raises Price Target to $830, Maintains Buy Rating | IDXX Stock News
Decoding IDEXX Laboratories Inc (IDXX): A Strategic SWOT Insight
Decoding IDEXX Laboratories Inc (IDXX): A Strategic SWOT Insight
IDEXX Laboratories (IDXX) Reports Strong Q3 2025 Financial Performance
IDEXX Laboratories (IDXX) Reports Strong Q3 2025 Financial Performance
IDEXX Laboratories Jumps 15% on Q3 Earnings Beat
IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance. The stock was...
Why Idexx Laboratories Stock Surged by Almost 15% Today
Key PointsIt notched a beat-and-raise third quarter.